CC
MRTX

Centiva Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Centiva Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-200
Closed -$14K – 1723
2022
Q3 		$14K Sell
200
-825
-80% -$61K ﹤0.01% 1391
2022
Q2 		$69K Buy
+1,025
New +$65.2K ﹤0.01% 1462
2021
Q4 		– Sell
-1,071
Closed -$189K – 1614
2021
Q3 		$189K Sell
1,071
-3,645
-77% -$586K 0.01% 946
2021
Q2 		$762K Sell
4,716
-641
-12% -$103K 0.02% 676
2021
Q1 		$918K Buy
5,357
+1,051
+24% +$208K 0.04% 389
2020
Q4 		$946K Buy
4,306
+2,649
+160% +$573K 0.04% 283
2020
Q3 		$275K Sell
1,657
-5,402
-77% -$739K 0.02% 499
2020
Q2 		$806K Buy
+7,059
New +$685K 0.05% 211

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Centiva Capital's MRTX Position: Q4 2022 in Review

Centiva Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 200 shares — an estimated $14K sold.

Centiva Capital first reported a position in MRTX in Q2 2020 and held it in 8 quarters. The position peaked at $946K in Q4 2020. 232 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

  • Centiva Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Centiva Capital sold 200 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $14K.
  • Centiva Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
  • Centiva Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $946K in Q4 2020.
  • 232 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Centiva Capital's 13F filing for Q4 2022, filed 14 Feb 2023.